Table 3.
Average annual 7-valent pneumococcal conjugate vaccine (PCV7) and PCV7-related serotype replacement (PCV7SR) cases and mortality pre- and post-introduction of the vaccination program in Alberta
| PCV7 cases (N) | PCV7SR cases (N) | Net annual difference in cases (N) | |||||
|---|---|---|---|---|---|---|---|
| Average pre-introduction (2000–2001) | Average post-introduction (2003–2008) | Annual difference post- versus pre-introduction | Average pre-introduction (2000–2001) | Average post-introduction (2003–2008) | Annual difference post- versus pre-introduction | ||
| Hospitalized pneumonia | 177.1 | 79 | 97.9 | 23 | 136 | −113.3 | −15.4 |
| Bacteremia | 40 | 20 | 20.3 | 2 | 3 | −0.9 | 19.3 |
| Meningitis | 4 | 1 | 2.3 | 0 | 0 | −0.1 | 2.2 |
| Non-hospitalized bacteria not getting worse | 14 | 5 | 8.3 | 1 | 1 | −0.4 | 8.0 |
| Non-hospitalized bacteria getting worse (10 %) | 1 | 1 | 0.9 | 0 | 0 | 0.0 | 0.8 |
| Mortality | 9.7 | 5.4 | 4.3 | 4.2 | 6.0 | −1.8 | 2.5 |